A5083582967- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- Protein Degradation and Inhibitors
- Lung Cancer Treatments and Mutations
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer-related gene regulation
- Hematopoietic Stem Cell Transplantation
Soochow University
2023-2025
First Affiliated Hospital of Soochow University
2023-2025
Treatment-free remission (TFR) has become the main target for chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKI) dose optimization is crucial in managing adverse events, and improving adherence clinical practice. In persons achieving a deep molecular response (DMR), some data suggest TKI reduction before discontinuation does not change success rate of TFR, but this controversial. However, on quality-of-life (QoL) mental health CML patients with full-dose TKI, low-dose are...
Abstract Myeloproliferative neoplasms (MPNs) with concurrent BCR‐ABL1 fusion gene and CALR mutation are especially rare. We report a patient coexisting gene, CALR, TET2 mutations who was treated the combination of second‐generation TKI nilotinib JAK1/JAK2 inhibitor ruxolitinib.
The data that support the findings of this study are available on request from corresponding author. not publicly due to privacy or ethical restrictions. Supplementary Table 1 result RNA sequencing for PAX5-MLLT3 fusion gene. 2 Clinical characteristics four patients genes. Please note: publisher is responsible content functionality any supporting information supplied by authors. Any queries (other than missing content) should be directed author article.